Several studies already demonstrated the importance of knocking down ERG over-expression by siRNA in prostate cancer [13, 36–38]; one of them has suggested the targeting of TMPRSS2-ERG fusion with siRNA delivered via liposomal nanovectors. This evidence concerns the gene TMPRSS2 and prostate carcinoma.